Asthma or exercise-induced bronchoconstriction is highly prevalent in athletes and if untreated has the potential to impact on their health and performance. The condition can be diagnosed and managed effectively yet there is concern that the care afforded to elite athletes with this condition is often suboptimal. In this respect, it is apparent that more could be done to protect athletes from developing airway dysfunction (eg, by reducing exposure to irritant environments); that the diagnosis of asthma in athletes is often made without secure objective evidence and that athletes may be advised to reduce activity levels in order to improve symptoms. Moreover there appears to be poor surveillance of airway health in athletes when a diagnosis of asthma has been made. Overall this raises the question of who cares about athletes with asthma? The article that follows present the case of why this is an important clinical area for physicians. The review provides an overview of asthma in athletes with the overall aim of ensuring that respiratory health in this unique population is optimized.
A sthma or exercise-induced bronchoconstriction (EIB) is highly prevalent in athletes. 1, 2 Indeed it is estimated that up to half of athletes partaking in certain sports (eg, swimming) have evidence of "asthma" and as such it is the most frequently encountered chronic medical condition in Olympic athletes. 3 On the face of it, the condition would appear to be relatively simple to assess and manage. However, as this article outlines, this is often not the case and as a consequence there is legitimate concern that the care afforded to elite athletes with asthma is often suboptimal. [4] [5] [6] [7] [8] Debate and controversy in the field of "asthma in athletes" usually begins with a definition of the condition. 9 In this respect, it is clear that many athletes with "asthma" have respiratory symptoms confined to the exercise period alone and as such do not describe features characteristic of "classical" asthma, for example, nocturnal symptoms. In this population the condition may thus be better described by the physiologically descriptive term-EIB; a transient airway narrowing occurring in association with exercise. 10 Further difficulties arise when the criteria for a diagnosis of asthma/EIB are considered. It is now established that a "symptom-based" approach to diagnosis is imprecise and that objective tests are required to ensure a diagnosis is secure. 5, 11 Despite this it is apparent that even at the elite level of the sport, the diagnosis of asthma in an athlete is often based entirely on a clinical appraisal or with support from tests with poor diagnostic precision (eg, peak flow monitoring). 4, 11 Moreover, when an athlete is diagnosed accurately there is often poor surveillance of their airway function following commencement of treatment, with the responsibility of clinical follow-up often falling to a sports team doctor without respiratory medicine expertise; for example, an orthopedic specialist. 12 This is remarkable given the impact of marginal physiological gains for performance in athletes competing at the elite or professional level.
It is also now increasingly apparent that exercise hyperpnea, particularly in certain environments (eg, indoor swimming), may be detrimental to the respiratory health of athletes. In this respect, it has been argued that exercise itself may actually cause airway "injury" in athletes 13 ; prompting the development of airway dysfunction and respiratory symptoms. Regardless of the underlying mechanisms, it is apparent that more could be done to protect athletes from developing airways disease (ie, by reducing exposure to irritant environments). 14 Overall these issues beg the question-who cares about elite athletes with asthma? It is the aim of this article to present the case of why this is an important area of respiratory medicine. The review describes the characteristics of asthma/EIB in athletes and highlights the current state of knowledge in terms of the best way to detect and manage asthma in elite athletes.
WHY CARE ABOUT ASTHMA IN ELITE ATHLETES?
It is generally accepted that for a condition to be considered clinically "relevant" and of interest, the condition should: (i) be prevalent; (ii) have an impact on an affected individual; (iii) be accurately diagnosed; and finally (iv) have effective treatment. There is a now a good body of published evidence to provide relevant support for each of these considerations with regards to asthma in the athletic population. The following section addresses these criteria in turn.
Prevalence
A considerable quantity of published data now exists detailing the prevalence of asthma and EIB in athletes ( Table 1) . The prevalence estimates vary significantly dependent on differences between studies in definition, diagnostic methods and techniques, population, subject sex and age, country, season, environment, and sporting discipline. 8, 29, 33, 34 An additional factor relates to the inclusion of studies that use symptoms alone for diagnosis or a combination of symptom-questionnaire and provocation testing. It has generally been found that in studies using symptom-based criteria, prevalence tended to be <20%, whereas in those employing objective tests, the prevalence tended to be >20%. 8 Regardless, it is now accepted that the prevalence of asthma and EIB in elite athletes as a group is considerably greater than the general population and may be as much as five times greater in the Olympians 3 (equating to approximately 8% of athletes). Moreover, this increased prevalence is stable when assessed longitudinally; the prevalence of airways disease was 21.2% and 20.7% in the British Olympic Team at the 2000 and 2004 Olympic Games, respectively. 29 A particularly high prevalence of asthma is reported in athletes competing in irritant-laden or noxious environments; for example, indoor swimming or cross-country skiing. This may relate to the impact of a high-ventilatory demand interacting with an environmental insult ( Table 2 ). For instance, the prevalence of asthma in cross-country skiers is approximately 15% to 20%, 3 however, in contrast, the prevalence in athletes partaking in ski-jump competition (comparable conditions without the high-ventilatory demand) is only 4%. 14 
Similar
findings have been observed in pool-based sports in which it has been reported that 20% to 40% of Olympic swimmers have evidence of airway disease, 3, 29 whereas data from indoor divers indicates a prevalence of merely B4% (IOC Independent Asthma Panel, 2002 to 2011). The prevalence of EIB in athletes performing sports that require neither a high-ventilatory demand, nor are performed in noxious environments (eg, table tennis and shooting) is likely to be similar to that expected in the general population. 3, 29 Accordingly, there is an evolving literature examining the role of noxious environments in causing an insult or "injury" to the airways. 13, 14, 35 Indeed when airway samples are studied 20 , provocative concentration (causing a fall in 20% in FEV 1 ); PD 20 , provocative dose (causing a fall in 20% in FEV 1 ); SS, sport-specific exercise challenge. from certain athletic groups (eg, cross-country skiiers) there is evidence of pathobiological damage that has a pattern akin to a biological injury 36, 37 (Fig. 1 ).
Impact of the Condition
In the athletic population, the impact or consequence of a diagnosis of asthma can be considered two-fold; firstly and perhaps most importantly in terms of impact on health and secondly on athletic performance.
The health impact of asthma is typically considered by evaluating the consequences of the condition on quality of life but also morbidity (eg, exacerbations) and mortality. There is currently a paucity of data specifically evaluating these outcomes in athletes with asthma. Moreover, data from a longitudinal study evaluating the lifetime occurrence and impact of asthma indicate that a prior diagnosis of asthma in former athletes had no long-term consequence. 39 In support of this, more recent work reveals that airways hyperreactivity witnessed in certain groups of athletes (eg, swimmers) is a transient phenomenon that improves within a short period of training cessation. 40 This acknowledged, one study reported that a high proportion of asthma-related deaths occur in elite or competitive athletes (57%) in close association with a sporting event. 41 A further study revealed that asthma was a significant risk for unexplained death in young athletically fit adults. 42 It is recognized that athletes are generally more likely to report coryzal symptoms that is, those typically associated with upper respiratory-tract infections. 43, 44 It has been proposed that the relative risk of developing upper respiratory-tract infection symptoms may be heightened during periods of prolonged, high-intensity physical activity (ie, elite endurance athletes).
In a study evaluating underlying cause(s) for recurrent infection in athletes, a new diagnosis and/or the presence of poorly controlled asthma was found to be a common explanation (13% of athletes investigated). 45 Differentiating an infective from noninfective etiology of respiratory-tract symptoms in athletes, however, is difficult given the overlap between symptoms; that is, symptoms are nonspecific and may relate to drying of the airway mucosal surfaces. 46 Thus, a definitive association between asthma and a heightened prevalence of respiratory-tract infection has yet to be established.
In the elite athletic population a crucial consideration is the impact of asthma or EIB on athletic performance. Several studies have now specifically examined this issue although it remains an area of active research.
Stensrud et al 47 reported that for athletes with EIB, exercising in a humid environment (19.91C and 95% relative humidity) improved exercise capacity compared to training in normal ambient conditions (20.21C and 40% relative humidity). Moreover, they also showed that exercise performance in a cold environment was diminished in this population. 48 Several studies have evaluated the influence of asthma treatment on performance. In healthy individuals without evidence of airways disease, it is now established that inhaled asthma medication, when administered at standard therapeutic doses, has no impact on the athletic performance. 49 However, in athletes with EIB, Brukner et al 50 found that regular inhaled asthma preventative medication increased peak oxygen uptake in a small number (n = 12) of football players.
Despite this, we 51 and other investigators 52 have failed to find any impact of treating EIB on performance in a sport-specific exercise test. Moreover, Sonna et al 53 screened a cohort of US Army recruits and found that EIB did not hinder physical performance during basic training; peak oxygen uptake levels and Army Physical Fitness Test scores were not significantly different between individuals with and without EIB.
Overall, key differences in study methodologies employed continue to make it difficult to draw robust conclusions regarding EIB and performance in athletes and further work is needed in this area.
Diagnosis
Extensive investigation over the past 30 years has highlighted an important yet often overlooked fact in the field of EIB in athletes. That is, that symptoms correlate poorly with objective evidence of exercise-associated airway narrowing. 7, 11, 27 This poor association has been repeatedly demonstrated in athletes from a broad range of sporting disciplines and acts to limit the accuracy of a symptom-based method for diagnosis. Indeed Rundell et al 27 concluded that basing a diagnosis of asthma or EIB on clinical symptoms alone in an athlete was likely to be as (im) precise as a coin toss.
The reason for this discrepancy remains to be determined but may relate to a high prevalence of conditions that mimic asthma. 12 In this respect a recent study 7 indicated that a high proportion of young athletes with exercise-associated dyspnea develop a transient narrowing that occurs at the level of the larynx causing the development of wheeze and dyspnea; termed exercise-induced laryngeal obstruction (EILO). In this study, athletes referred with dyspnea completed a comprehensive assessment of their lung function, bronchial hyperreactivity, and airway inflammation. They also completed a nasendoscopic evaluation of their laryngeal movementrecorded continuously during exercise. Of the 88 athletes completing assessment, approximately one third had evidence of EILO as an explanation for their exercise-related symptoms. It is important to note that the majority of these athletes were taking, or had previously been prescribed, inhaled asthma therapy and that it was not possible to differentiate those with or without EILO on the basis of clinical features alone.
This finding has important diagnostic and treatment implications and highlights a problem for physicians encountering athletes who have unexplained symptoms and/or symptoms that are "refractory" to treatment. Athletes are often misdiagnosed as having "asthma" following a diagnostic assessment based on clinical features alone (ie, without objective test confirmation). 6, 11 This is true even at the elite level of sport, where athletes are often labeled from an early stage in their career and on the basis of tests with a poor predictive value (eg, peak flow monitoring). 4, 11 The role of clinical assessment in this context should simply be to focus evaluation on features supporting a diagnosis of asthma, but with consideration for alternative diagnoses (eg, cardiac pathology). 54 A secure diagnosis then depends on confirmatory investigation (proposed assessment algorithm is presented in Fig. 2) .
It has been argued that a sports-specific exercise field test, simulating the exercise environment and demonstrating a reduction in airflow, represents the true "gold-standard" method for making a diagnosis of EIB. However, exercise challenge tests are not recommended as a first-line investigation given their poor sensitivity for diagnosis and difficulty to perform reliably. 55 A bronchial provocation challenge is therefore often necessary to establish evidence of variable airflow obstruction, that is, to demonstrate airway narrowing in response to a provocation that mimics exercise (eg, dry, cold gas). More specifically, an athlete performs serial spirometry tests before and following a challenge; typically looking for a 10% fall in forced expiratory volume (FEV 1 ) from baseline values. 56 The International Olympic Committee currently favors eucapnic voluntary hyperpnea testing as the gold-standard test to accurately diagnose airway dysfunction in athletes. However, alternative accepted diagnostic challenges include bronchodilator reversibility and laboratory/field exercise testing, methacholine, saline, or dry powder mannitol challenges. 57 
Treatment
The treatment of asthma in athletes is well established and is in the most part straightforward and effective. 58 Both pharmacological and nonpharmacological therapies play an important role in management.
In terms of nonpharmacological management, it is recommended that athletes should perform a dedicated warm-up (ie, bursts of high-intensity exercise interspersed with periods of low-intensity exercise) 59 to take potential advantage of the "refractory period"; defined as a period following warm-up during which further vigorous exercise results in significantly less severe or an absence of airway narrowing. Strategies to humidify the inspired air (eg, face muffle) may also prove beneficial. 60 Other studies have highlighted the importance of dietary manipulation as an adjunctive intervention. 58 Pharmacological therapies evaluated and shown to protect against EIB include inhaled b-2 agonists, inhaled corticosteroids, cromolyn compounds, and leukotriene modifiers. An inhaled short-acting b-2 agonist administered before exercise is usually effective in negating EIB and forms the mainstay of pharmacological treatment. 58 Beyond this however, there is a lack of consensus with regards to the optimum choice, timing of initiation, or dose of regular preventative medication. It has been recommended that an athlete who has asthma symptoms outside the setting of exercise or who is using b-2 agonist medication (ie, >3 times per week) should be treated with anti-inflammatory agent; for example, regular inhaled corticosteroid or an oral leukotriene antagonist. However, for an elite athlete it is commonplace to train twice daily and as such this advice is effectively obsolete. The current best evidence with regards to treatment of EIB is presented in the recent American Thoracic Society Guidelines. 58 Clinicians should also be aware that some medications used for the treatment of asthma are prohibited for use by the World Anti-Doping Agency. The list of prohibited asthma medications has diminished considerably over the past 5 years, however, there remain notable exceptions and it is therefore advisable to view http://www.globaldro.org or consult with the relevant national anti-doping agency to ensure that an athlete remains compliant with regulations from their sporting body.
WHO CURRENTLY CARES FOR ELITE ATHLETES WITH ASTHMA?
In the United Kingdom, it is common for primary care physicians to regularly encounter patients with exercise-related respiratory symptoms. 4 Moreover, in an 1-year period (2008 to 2009), approximately 70% of applications for asthma medication "therapeutic use exemption" forms (ie, the paperwork to permit an elite "national standard" or professional athlete to use asthma medication) was submitted by primary care physicians (N.
Wojek, Oral personal communication-UK Anti-Doping).
It is therefore of concern, that evidence suggests that the diagnosis and treatment of asthma/EIB in athletes is often not in keeping with guideline recommendations. Indeed in a questionnaire survey of primary care UK physicians, one third indicated that they would initiate treatment based on clinical information alone. 4 Moreover, although over two thirds of primary care physicians chose investigation as the initial course of action, the tests selected [eg, peak expiratory flow rate on exercise (44%) and resting spirometry prebronchodilator and postbronchodilator (35%)] are recognized to have poor diagnostic precision. Similar findings were apparent in a study evaluating primary care physicians' approach to EIB in the United States. 6 Overall, these findings have important implications regarding the quality of management of an athlete's respiratory health.
It could be argued that all elite athletes, and certainly members of an Olympic squad, should be "screened" for airway dysfunction. We have previously discussed the implications of implementing a widespread EIB screening policy in athletes highlighting the benefit versus harm of such a policy. 1 One important consequence to be considered in view of a heightened focus on diagnostic accuracy is the risk of overdiagnosis. 1, 8 In this respect it is becoming increasingly apparent that there exists a population of athletes who are asymptomatic, yet have been labeled as having "asthma" on the basis of airways hyperreactivity, that is, detected from a positive bronchoprovocation test. 61 The impact of a diagnosis of "asthma" in this population, both for the health and performance of an athlete remains to be established. On balance therefore general screening for asthma in athletes is not recommended, however, this may be appropriate in high-risk sporting groups (eg, swimmers). 58 Overall, it could be argued that given the complexities regarding diagnosis and surveillance it is ideal that athletes presenting with respiratory symptoms are referred to a sports physician or respiratory physician with expertise in this area. 
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WHO CARES ABOUT RESEARCHING ASTHMA IN ATHLETES?
There has been a steady increase in the number of manuscripts published in the field of asthma and EIB in athletes over the past 20 years (Fig. 3) . Recent work has focused on accuracy of clinical diagnosis, differential diagnosis, the impact of detraining on airways hyperreactivity, and presence of airway pathology and airway injury. Pharmacological and nonpharmacological management important Include-strategies to humidify the inspired air (eg, face muffle) Dietary modification (ie, omega-3 fish oils) Pharmacological prophylaxis to prevent EIB includes:
b-2 agonists, inhaled corticosteroids, cromolyn compounds, and leukotriene modifiers Impact of treatment on repeated bronchoprovocation in a "real-life" treatment trial-ie, in Olympic squad members Work needed to explore impact of primary prevention on long-term airway health (eg, face muffles in crosscountry skiers) EIB indicates exercise-induced bronchoconstriction.
However, the experience of many researchers studying EIB in athletes in Europe (variety of Oral personal communications) that research in this field remains underfunded by the major medical grant awarding bodies. This may relate to a perception from the funding bodies that when compared with other respiratory diseases the impact of airway dysfunction in a relatively fit young population is of low priority.
It remains, however, that exercise is the one of the most commonly reported symptom triggers in individuals with asthma, and dyspnea on exertion is a prominent and disabling clinical characteristic of the disease. 62 Undoubtedly, research in the field of EIB in young fit individuals has been of translational benefit for the general asthmatic population. Furthermore recent work evaluating airway injury and potential mechanisms to protect the airway of asthmatic athletes will be of likely benefit to the general asthmatic population.
Conclusions-Time to Care More About Asthma in Athletes
The purpose of this article was to present the case for why it is important to care about asthma in elite athletes. The evidence presented highlights a wealth of data indicating that asthma/EIB in athletes is highly prevalent, has an important potential impact on their health and performance, and can be diagnosed and treated effectively. Despite this, the review also details important deficiencies that remain in the current state of knowledge in this field (Table 3 ), supporting the fact that focus should remain on this condition with the aim of optimizing respiratory care in athletes.
